Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meclofenamate plus temozolomide in progressive MGMT-methylated glioblastoma at first relapse
2024-511264-89-00Phase 2Authorised
- Sponsor
- University of Bonn
- Start
- Apr 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Meclofenamic acid and temozolomide in glioblastoma (GBM) and Gliosarcoma (GS) (3 arms), sponsored by University of Bonn. Primary endpoints: Dose-limiting toxicities and Progression-free survival. Planned start Apr 2022; status: authorised.
02
Drugs
Meclofenamic acidtemozolomide
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on 2024-511264-89-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511264-89-00.